CSE bulletin 2026-1123
The common shares of Peptide Development Labs Inc. have been approved for listing on the Canadian Securities Exchange.
Listing and disclosure documents will be available on the CSE website on the listing date.
Peptide Development Labs is a Canadian pharmaceutical development company focused on advancing investigational peptide-based drug candidates through established regulatory pathways. The Issuer s mission is to develop peptide candidates that may address defined areas of unmet clinical need within a conventional pharmaceutical framework. To achieve this, the Issuer focuses on advancing its investigational subcutaneous BPC-157 drug candidate for refractory ligament disorders through GMP-controlled supply, pharmaceutical quality systems, physician-led access, structured data generation and formal clinical development.
Issuer: Peptide Development Labs
Security type: common shares
Symbol: PEPT
NV (non-venture) issuer: no
Number of securities issued and outstanding: 37,511,506
Number of securities reserved for issuance: three million
CSE sector: life sciences
Cusip No.: 713467 10 8
ISIN: CA 713467 10 8 9
Board lot: 500
Trading currency: Canadian dollar
Listing date: Nov. 20, 2026
Other exchanges: not applicable
Fiscal year-end: Sept. 30
Transfer agent: Odyssey Trust Company
The exchange is accepting market-maker applications for PEPT.
© 2026 Canjex Publishing Ltd. All rights reserved.